Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Sinzinger

Showing results (381-390 of 672) with videos related to

Pageof 68
Sort By:
European Journal of Nuclear Medicine|July 1, 1996
Bradykinin formation during processing for cellular labelling may cause side-effectsM Rodrigues, G Karanikas, S Granegger, et al.
Progress in Clinical and Biological Research|January 1, 1989
Increase in left ventricular ejection fraction (LVEF) induced by PGE1 and PGI2I Virgolini, C Auinger, M Weissel, et al.
Progress in Clinical and Biological Research|January 1, 1987
Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogueJ Kaliman, P Fitscha, H Barth, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1981
Some remarks on the complex behaviour of platelet function during and after prostacyclin treatmentH Sinzinger, K Silberbauer, C Leithner, et al.
American Journal of Hematology|February 1, 1990
Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigationH Sinzinger, F Rauscha, P Fitscha, et al.
Wiener Klinische Wochenschrift|April 14, 1989
[Effects of omega-3-fatty acids on the prostaglandin system in healthy probands]A Gazsó, J Kaliman, D F Horrobin, et al.
Prostaglandins|January 1, 1981
Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon?H Sinzinger, K Silberbauer, A K Horsch, et al.
Lancet (London, England)|April 13, 1991
Calcium antagonists and hypercalcaemiaH Sinzinger, F Rauscha, P Fitscha, et al.
Wiener Klinische Wochenschrift|February 5, 1988
[Technic and clinical use of radioactive labelling of autologous granulocytes]E Strobl-Jäger, H Kolbe, H Ludwig, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 3, 1999
Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidationH Kritz, A Oguogho, A A Aghajanian, et al.
Pageof 68

Showing results (381-390 of 672) with videos related to

Sort By:
Pageof 68
European Journal of Nuclear Medicine|July 1, 1996
Bradykinin formation during processing for cellular labelling may cause side-effectsM Rodrigues, G Karanikas, S Granegger, et al.
Progress in Clinical and Biological Research|January 1, 1989
Increase in left ventricular ejection fraction (LVEF) induced by PGE1 and PGI2I Virgolini, C Auinger, M Weissel, et al.
Progress in Clinical and Biological Research|January 1, 1987
Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogueJ Kaliman, P Fitscha, H Barth, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1981
Some remarks on the complex behaviour of platelet function during and after prostacyclin treatmentH Sinzinger, K Silberbauer, C Leithner, et al.
American Journal of Hematology|February 1, 1990
Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigationH Sinzinger, F Rauscha, P Fitscha, et al.
Wiener Klinische Wochenschrift|April 14, 1989
[Effects of omega-3-fatty acids on the prostaglandin system in healthy probands]A Gazsó, J Kaliman, D F Horrobin, et al.
Prostaglandins|January 1, 1981
Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon?H Sinzinger, K Silberbauer, A K Horsch, et al.
Lancet (London, England)|April 13, 1991
Calcium antagonists and hypercalcaemiaH Sinzinger, F Rauscha, P Fitscha, et al.
Wiener Klinische Wochenschrift|February 5, 1988
[Technic and clinical use of radioactive labelling of autologous granulocytes]E Strobl-Jäger, H Kolbe, H Ludwig, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 3, 1999
Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidationH Kritz, A Oguogho, A A Aghajanian, et al.
Pageof 68